Show simple item record

dc.contributor.authorCarr, TH
dc.contributor.authorAdelman, C
dc.contributor.authorBarnicle, A
dc.contributor.authorKozarewa, I
dc.contributor.authorLuke, S
dc.contributor.authorLai, Z
dc.contributor.authorMenon, S
dc.contributor.authorHollis, S
dc.contributor.authorDougherty, B
dc.contributor.authorHarrington, EA
dc.contributor.authorBarrett, JC
dc.contributor.authorGoessl, C
dc.contributor.authorSaad, F
dc.contributor.authorSala, N
dc.contributor.authorClarke, Noel W
dc.contributor.authorHodgson, D
dc.date.accessioned2019-04-29T09:48:50Z
dc.date.available2019-04-29T09:48:50Z
dc.date.issued2018en
dc.identifier.citationCarr TH, Adelman C, Barnicle A, Kozarewa I, Luke S, Lai Z, et al. 97P Multimodal detection of homologous recombination repair gene mutations (HRRm) in a phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC). Annals of Oncology. 2018;29(suppl_8).en
dc.identifier.pmidNo PMIDen
dc.identifier.doi10.1093/annonc/mdy269.095en
dc.identifier.urihttp://hdl.handle.net/10541/621712
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy269.095en
dc.titleMultimodal detection of homologous recombination repair gene mutations (HRRm) in a phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentAstraZeneca, Cambridge, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record